NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/26/2026
Back to search
Official data from USPTO
OXURION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
OXURION
ST13
US500000079239267Class
5, 42, 44
Filing
79239267
Registration
5772180
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
02/27/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
06/25/2018
Registration date
06/11/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/26/2025
Last transaction
02/27/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
32
Owner location
BE
Examiner
MESSICK, TABITHA LEE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Oxurion NV
ThromboGenics
Representatives
Martin W. Schiffmiller Kirschstein Israel Schiffmiller & Pieroni, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biopharmaceutical preparations for use in the treatment of hypertensionstrokescardiac diseases and vascular diseases; diagnostic medical reagentschemicals preparations and biological materials all the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnostingmonitoringpredicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertensionstrokescardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluidsophthalmic pharmaceutical preparations; pharmaceutical eye drops
Class 42
Scientific and technological servicesnamely research and design relating thereto in the field of ophthalmologyin the field of diabetes and in the field of treatment of cardiovascular diseasecardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseasesdiabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmologydiabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular diseasecardiac diseasevascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals
Class 44
Medical services; veterinary services; consultancy servicesconsultancy in the medicalveterinary and pharmaceutical treatment of patients in the fields of ophthalmologydiabetes and cardiovascular diseases; medical servicescardiac and vascular therapeuticprognostic and diagnostic testing services
Publications
History of USPTO decisions and trademark events.
32 publications found
C71T
CANCELLED SECTION 71
12/26/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/14/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/11/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/12/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/21/2019
FIMP
FINAL DISPOSITION PROCESSED
09/21/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/11/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/13/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
06/11/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/26/2019
PUBO
PUBLISHED FOR OPPOSITION
03/26/2019
GPNX
NOTIFICATION PROCESSED BY IB
03/23/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/06/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/06/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/06/2019
ALIE
ASSIGNED TO LIE
02/15/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/02/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/30/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/30/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/30/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/30/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/30/2019
RFNT
REFUSAL PROCESSED BY IB
11/09/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/25/2018
RFRR
REFUSAL PROCESSED BY MPU
10/25/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/14/2018
CNRT
NON-FINAL ACTION WRITTEN
10/13/2018
DOCK
ASSIGNED TO EXAMINER
10/13/2018
MAFR
APPLICATION FILING RECEIPT MAILED
08/28/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/24/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/23/2018
Continuous trademark protection
Get notified about every new filing that threatens OXURION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.